Floatz logo

JYP0322

Lung Neoplasms

Guangzhou JOYO Pharma Co., LtdPhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

51 Active assets in the Lung Neoplasms cohort.

Asset / SponsorPhaseRating
Carboplatin
Nanfang Hospital, Southern Medical University
Phase 4BB
BELAGENPUMATUCEL-L (SK-LU-1)
NovaRx Corporation
Phase 3BB
Nivolumab
Hospital Israelita Albert Einstein
Phase 2BB
Icotinib
Fuda Cancer Hospital, Guangzhou
Phase 4BB
Cyclophosphamide
Pfizer
Phase 3BB

View all 50 →

Same molecule, other indications

JYP0322 is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
Protein Kinase InhibitorsDormant
CC
Indicative ·
43 / 100
View asset →
brain neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →